<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03002519</url>
  </required_header>
  <id_info>
    <org_study_id>PLX-R18-HCT-01</org_study_id>
    <nct_id>NCT03002519</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation</brief_title>
  <official_title>A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pluristem Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pluristem Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety of intramuscular (IM) administration of PLX-R18 in
      subjects with incomplete hematopoietic recovery following HCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2017</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Emergent Adverse Events (AEs)</measure>
    <time_frame>Recorded after time of consent throughout the study until the last visit (~1 year)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety laboratory values (including immunological testing)</measure>
    <time_frame>Blood samples will be collected on each visit, through study completion (~1 year)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Will be assessed during each visit, through study completion (~1 year)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>ECG</measure>
    <time_frame>Will be assessed during the screening visit, before each IP treatment visit and on the 14th day of participation (visit 5).</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Incomplete HCT (Hematopoietic Cell Transplantation)</condition>
  <arm_group>
    <arm_group_label>PLX-R18</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation- first three subjects will be enrolled in the low dose cohort, 12 subjects in the intermediate-dose cohort, and 15 subjects in the high dose cohort.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PLX-R18</intervention_name>
    <description>Intramuscular (IM) administration of PLX-R18</description>
    <arm_group_label>PLX-R18</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years.

          2. At least 4 months after HCT, either autologous or allogeneic (of any source, with any
             preparatory regimen, for any indication), prior to study treatment.

          3. Sustained platelet count ≤50,000/µL, and/or sustained Hgb ≤8 g/dL and/or sustained ANC
             ≤1000/mm3, which is considered by the Investigator as related to the nature of the
             graft (higher transient levels following occasional blood product transfusions are
             allowed).

          4. Stable donor cell chimerism in at least 3 consecutive tests prior to treatment.

          5. If the subject had allogeneic HCT for a malignant disease, the subject should have
             complete donor chimerism. (*complete donor chimerism determined by the investigator
             per site's standards)

          6. General performance status evaluated by ECOG 0-2 scale.

        Exclusion Criteria:

          1. Evidence of active malignancy at the time of HCT or at any time since the HCT.

          2. No other known etiology of the thrombocytopenia (such as infection, medication, etc.)
             or anemia (such as blood loss, iron deficiency, etc.).

          3. Current active infection requiring systemic treatment.

          4. Acute graft versus host disease (GvHD) Grade III or IV, or severe chronic GvHD.

          5. History of malignancy (other than the disease that required the HCT) within 5 years
             prior to screening.

          6. History of severe allergic/hypersensitivity reaction or significant transfusion
             reaction.

          7. Severe or uncontrolled/unstable cardiac, pulmonary, hepatic or renal disease,
             including MI or CVA within 3 months prior to treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1447</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Bishop, M.D</last_name>
      <phone>773-702-9297</phone>
      <email>mbishop@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Bishop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Rowley, MD</last_name>
      <phone>201-996-5897</phone>
      <email>srowley@humed.com</email>
    </contact>
    <investigator>
      <last_name>Scott Rowley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leland Metheny, MD</last_name>
      <phone>216-983-0771</phone>
      <email>leland.metheny@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Leland Metheny, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Escobar, M.D</last_name>
      <phone>214-370-1500</phone>
      <email>carolina.escobar@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carolina Escobar, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsila Zuckerman, Prof.</last_name>
      <phone>+972 (4) 777-3248</phone>
      <email>t_zuckerman@rambam.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Hila Wildbaum</last_name>
      <phone>+972 (4) 777-3248</phone>
      <email>H_WILDBAUM@rambam.health.gov.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Batia Avni, Dr.</last_name>
      <phone>+972508573250</phone>
      <email>BATIAA@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Liliane Dray</last_name>
      <phone>+972508573250</phone>
      <email>LILANE@hadassah.org.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2016</study_first_submitted>
  <study_first_submitted_qc>December 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

